BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goldsmith DR, Haroon E, Miller AH, Strauss GP, Buckley PF, Miller BJ. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res 2018;199:281-4. [PMID: 29499967 DOI: 10.1016/j.schres.2018.02.048] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Feng A, Luo N, Zhao W, Calhoun VD, Jiang R, Zhi D, Shi W, Jiang T, Yu S, Xu Y, Liu S, Sui J. Multimodal brain deficits shared in early-onset and adult-onset schizophrenia predict positive symptoms regardless of illness stage. Hum Brain Mapp 2022. [PMID: 35388581 DOI: 10.1002/hbm.25862] [Reference Citation Analysis]
2 Ventura J, McEwen S, Subotnik KL, Hellemann GS, Ghadiali M, Rahimdel A, Seo MJ, Irwin MR, Nuechterlein KH. Changes in inflammation are related to depression and amount of aerobic exercise in first episode schizophrenia. Early Interv Psychiatry 2021;15:213-6. [PMID: 32056388 DOI: 10.1111/eip.12946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Zhu M, Liu Z, Guo Y, Sultana MS, Wu K, Lang X, Lv Q, Huang X, Yi Z, Li Z. Sex difference in the interrelationship between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia. J Neuroinflammation 2021;18:202. [PMID: 34526062 DOI: 10.1186/s12974-021-02261-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Misiak B, Ricceri L, Sąsiadek MM. Transposable Elements and Their Epigenetic Regulation in Mental Disorders: Current Evidence in the Field. Front Genet 2019;10:580. [PMID: 31293617 DOI: 10.3389/fgene.2019.00580] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
5 Amoli MM, Khatami F, Arzaghi SM, Enayati S, Nejatisafa A. Over-expression of TGF-β1 gene in medication free Schizophrenia. Psychoneuroendocrinology 2019;99:265-70. [DOI: 10.1016/j.psyneuen.2018.10.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhu S, Zhao L, Fan Y, Lv Q, Wu K, Lang X, Li Z, Yi Z, Geng D. Interaction between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia. Psychoneuroendocrinology 2020;114:104595. [DOI: 10.1016/j.psyneuen.2020.104595] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
7 Shivakumar V, Sreeraj VS, Subbanna M, Kalmady SV, Amaresha AC, Narayanaswamy JC, Debnath M, Venkatasubramanian G. Differential impact of interleukin-6 promoter gene polymorphism on hippocampal volume in antipsychotic-naïve schizophrenia patients. Indian J Psychiatry 2020;62:36-42. [PMID: 32001929 DOI: 10.4103/psychiatry.IndianJPsychiatry_486_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine Alterations in Schizophrenia: An Updated Review. Front Psychiatry 2019;10:892. [PMID: 31908647 DOI: 10.3389/fpsyt.2019.00892] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 16.3] [Reference Citation Analysis]
9 Prestwood TR, Asgariroozbehani R, Wu S, Agarwal SM, Logan RW, Ballon JS, Hahn MK, Freyberg Z. Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. Behav Brain Res 2021;402:113101. [PMID: 33453341 DOI: 10.1016/j.bbr.2020.113101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Valiuliene G, Valiulis V, Dapsys K, Vitkeviciene A, Gerulskis G, Navakauskiene R, Germanavicius A. Brain stimulation effects on serum BDNF, VEGF, and TNFα in treatment-resistant psychiatric disorders. Eur J Neurosci 2021;53:3791-802. [PMID: 33861484 DOI: 10.1111/ejn.15232] [Reference Citation Analysis]
11 Feng T, McEvoy JP, Miller BJ. Longitudinal study of inflammatory markers and psychopathology in schizophrenia. Schizophr Res 2020;224:58-66. [PMID: 33289658 DOI: 10.1016/j.schres.2020.10.003] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jankowska U, Skupien-Rabian B, Swiderska B, Prus G, Dziedzicka-Wasylewska M, Kedracka-Krok S. Proteome Analysis of PC12 Cells Reveals Alterations in Translation Regulation and Actin Signaling Induced by Clozapine. Neurochem Res 2021;46:2097-111. [PMID: 34024016 DOI: 10.1007/s11064-021-03348-4] [Reference Citation Analysis]
13 Ermakov EA, Dmitrieva EM, Parshukova DA, Kazantseva DV, Vasilieva AR, Smirnova LP. Oxidative Stress-Related Mechanisms in Schizophrenia Pathogenesis and New Treatment Perspectives. Oxid Med Cell Longev 2021;2021:8881770. [PMID: 33552387 DOI: 10.1155/2021/8881770] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 McGrath T, Baskerville R, Rogero M, Castell L. Emerging Evidence for the Widespread Role of Glutamatergic Dysfunction in Neuropsychiatric Diseases. Nutrients 2022;14:917. [PMID: 35267893 DOI: 10.3390/nu14050917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hei G, Smith RC, Li R, Ou J, Song X, Zheng Y, He Y, Arriaza J, Fahey JW, Cornblatt B, Kang D, Yang Y, Huang J, Wang X, Cadenhead K, Zhang M, Davis JM, Zhao J, Jin H, Wu R. Sulforaphane Effects on Cognition and Symptoms in First and Early Episode Schizophrenia: A Randomized Double-Blind Trial. Schizophrenia Bulletin Open 2022;3:sgac024. [DOI: 10.1093/schizbullopen/sgac024] [Reference Citation Analysis]
16 Ioannou M, Foiselle M, Mallet J, Stam EL, Godin O, Dubertret C, Terro E, Sommer IEC, Haarman BCM, Leboyer M, Schoevers RA. Towards precision medicine: What are the stratification hypotheses to identify homogeneous inflammatory subgroups. Eur Neuropsychopharmacol 2021;45:108-21. [PMID: 33189523 DOI: 10.1016/j.euroneuro.2020.11.001] [Reference Citation Analysis]
17 Paudel YN, Shaikh MF, Shah S, Kumari Y, Othman I. Role of inflammation in epilepsy and neurobehavioral comorbidities: Implication for therapy. Eur J Pharmacol 2018;837:145-55. [PMID: 30125565 DOI: 10.1016/j.ejphar.2018.08.020] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 12.0] [Reference Citation Analysis]
18 Goldsmith DR, Massa N, Pearce BD, Wommack EC, Alrohaibani A, Goel N, Cuthbert B, Fargotstein M, Felger JC, Haroon E, Miller AH, Duncan E. Inflammatory markers are associated with psychomotor slowing in patients with schizophrenia compared to healthy controls. NPJ Schizophr 2020;6:8. [PMID: 32238816 DOI: 10.1038/s41537-020-0098-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Enache D, Nikkheslat N, Fathalla D, Morgan BP, Lewis S, Drake R, Deakin B, Walters J, Lawrie SM, Egerton A, MacCabe JH, Mondelli V. Peripheral immune markers and antipsychotic non-response in psychosis. Schizophr Res 2021;230:1-8. [PMID: 33667853 DOI: 10.1016/j.schres.2020.12.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Goldsmith DR, Haroon E, Miller AH, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Seidman L, Tsuang M, Woods SW, Walker EF, Perkins DO. Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain Behav Immun 2019;76:268-74. [PMID: 30496778 DOI: 10.1016/j.bbi.2018.11.315] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
21 Wedervang-Resell K, Friis S, Lonning V, Smelror RE, Johannessen C, Reponen EJ, Lyngstad SH, Lekva T, Aukrust P, Ueland T, Andreassen OA, Agartz I, Myhre AM. Increased interleukin 18 activity in adolescents with early-onset psychosis is associated with cortisol and depressive symptoms. Psychoneuroendocrinology 2020;112:104513. [PMID: 31761332 DOI: 10.1016/j.psyneuen.2019.104513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
22 Li M, Qiu Y, Zhang J, Zhang Y, Liu Y, Zhao Y, Jia Q, Fan X, Li J. Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2022. [PMID: 35037116 DOI: 10.1007/s00406-021-01359-4] [Reference Citation Analysis]
23 Dai N, Jie H, Duan Y, Xiong P, Xu X, Chen P, Kang M, Li M, Li T, Huang Z, Chen H. Different serum protein factor levels in first-episode drug-naive patients with schizophrenia characterized by positive and negative symptoms. Psychiatry Clin Neurosci 2020;74:472-9. [PMID: 32478952 DOI: 10.1111/pcn.13078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gómez-Rubio P, Trapero I. The Effects of Exercise on IL-6 Levels and Cognitive Performance in Patients with Schizophrenia. Diseases 2019;7:E11. [PMID: 30678202 DOI: 10.3390/diseases7010011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Chauhan P, Kaur G, Prasad R, Singh H. Pharmacotherapy of schizophrenia: immunological aspects and potential role of immunotherapy. Expert Rev Neurother 2021;:1-13. [PMID: 34654348 DOI: 10.1080/14737175.2021.1994857] [Reference Citation Analysis]
26 Krynicki CR, Dazzan P, Pariante CM, Barnes NM, Vincent RC, Roberts A, Giordano A, Watson A, Suckling J, Barnes TRE, Husain N, Jones PB, Joyce E, Lawrie SM, Lewis S, Deakin B, Upthegrove R; BeneMin Study team. Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain Behav Immun 2021;91:498-504. [PMID: 33161162 DOI: 10.1016/j.bbi.2020.10.026] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Morris G, Puri BK, Olive L, Carvalho AF, Berk M, Maes M. Emerging role of innate B1 cells in the pathophysiology of autoimmune and neuroimmune diseases: Association with inflammation, oxidative and nitrosative stress and autoimmune responses. Pharmacological Research 2019;148:104408. [DOI: 10.1016/j.phrs.2019.104408] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
28 Li M, Liu Y, Qiu Y, Zhang J, Zhang Y, Zhao Y, Jia Q, Li J. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res 2021;300:113899. [PMID: 33812218 DOI: 10.1016/j.psychres.2021.113899] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
29 Lin C, Chen K, Yu J, Feng W, Fu W, Yang F, Zhang X, Chen D. Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients. BMC Psychiatry 2021;21:561. [PMID: 34763685 DOI: 10.1186/s12888-021-03569-5] [Reference Citation Analysis]
30 Thylur DS, Goldsmith DR. Brick by Brick: Building a Transdiagnostic Understanding of Inflammation in Psychiatry. Harv Rev Psychiatry 2022;30:40-53. [PMID: 34995034 DOI: 10.1097/HRP.0000000000000326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Guessoum SB, Le Strat Y, Dubertret C, Mallet J. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 2020;99:109862. [PMID: 31927053 DOI: 10.1016/j.pnpbp.2020.109862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
32 Misiak B, Bartoli F, Carrà G, Stańczykiewicz B, Gładka A, Frydecka D, Samochowiec J, Jarosz K, Hadryś T, Miller BJ. Immune-inflammatory markers and psychosis risk: A systematic review and meta-analysis. Psychoneuroendocrinology 2021;127:105200. [PMID: 33740587 DOI: 10.1016/j.psyneuen.2021.105200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Subbanna M, Shivakumar V, Venugopal D, Narayanaswamy JC, Berk M, Varambally S, Venkatasubramanian G, Debnath M. Impact of antipsychotic medication on IL-6/STAT3 signaling axis in peripheral blood mononuclear cells of drug-naive schizophrenia patients. Psychiatry Clin Neurosci 2020;74:64-9. [PMID: 31587436 DOI: 10.1111/pcn.12938] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
34 Zhang L, Liu F, Zheng H, Wu R, Zhao J. Serum Interleukin-1β and tumor necrosis factor-α in first-episode drug-naive and chronic schizophrenia patients: Associated with cognitive deficits. Asian J Psychiatr 2021;58:102605. [PMID: 33636450 DOI: 10.1016/j.ajp.2021.102605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Chaves CB, Vieira-coelho MA. Clinical trials with monoclonal antibodies in schizophrenia. Schizophrenia Research 2020;222:511-3. [DOI: 10.1016/j.schres.2020.05.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Strauss GP, Macdonald KI, Ruiz I, Raugh IM, Bartolomeo LA, James SH. The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia. Eur Arch Psychiatry Clin Neurosci 2021. [PMID: 33881621 DOI: 10.1007/s00406-021-01260-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
37 Severance EG, Yolken RH. Tracking a dysregulated gut-brain axis with biomarkers of the microbiome. Biomarkers in Neuropsychiatry 2020;2:100009. [DOI: 10.1016/j.bionps.2019.100009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
38 Dunleavy C, Elsworthy RJ, Upthegrove R, Wood SJ, Aldred S. Inflammation in first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. Acta Psychiatr Scand 2022. [PMID: 35202480 DOI: 10.1111/acps.13416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
39 Abdolalizadeh A, Ostadrahimi H, Ohadi MAD, Saneei SA, Bayani Ershadi AS. White matter microstructural associates of apathy-avolition in schizophrenia. J Psychiatr Res 2021;142:110-6. [PMID: 34332375 DOI: 10.1016/j.jpsychires.2021.07.042] [Reference Citation Analysis]
40 Strauss GP. A Bioecosystem Theory of Negative Symptoms in Schizophrenia. Front Psychiatry 2021;12:655471. [PMID: 33841217 DOI: 10.3389/fpsyt.2021.655471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
41 Eissa N, Sadeq A, Sasse A, Sadek B. Role of Neuroinflammation in Autism Spectrum Disorder and the Emergence of Brain Histaminergic System. Lessons Also for BPSD? Front Pharmacol 2020;11:886. [PMID: 32612529 DOI: 10.3389/fphar.2020.00886] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
42 López-Díaz Á, Menéndez-Sampil C, Pérez-Romero A, Palermo-Zeballos FJ, Valdés-Florido MJ. Characterization of deficit schizophrenia and reliability of the bidimensional model of its negative symptomatology. Nord J Psychiatry 2020;74:400-6. [PMID: 32149549 DOI: 10.1080/08039488.2020.1736151] [Reference Citation Analysis]
43 Goldsmith DR, Massa N, Miller BJ, Miller AH, Duncan E. The interaction of lipids and inflammatory markers predict negative symptom severity in patients with schizophrenia. NPJ Schizophr 2021;7:50. [PMID: 34671033 DOI: 10.1038/s41537-021-00179-8] [Reference Citation Analysis]
44 Dzikowski M, Juchnowicz D, Dzikowska I, Rog J, Próchnicki M, Kozioł M, Karakula-Juchnowicz H. The Differences between Gluten Sensitivity, Intestinal Biomarkers and Immune Biomarkers in Patients with First-Episode and Chronic Schizophrenia. J Clin Med 2020;9:E3707. [PMID: 33218214 DOI: 10.3390/jcm9113707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
45 Li Z, Zhang T, Xu L, Wei Y, Tang Y, Hu Q, Liu X, Li X, Davis J, Smith R, Jin H, Wang J. Decreasing risk of psychosis by sulforaphane study protocol for a randomized, double-blind, placebo-controlled, clinical multi-centre trial. Early Interv Psychiatry 2021;15:585-94. [PMID: 32436318 DOI: 10.1111/eip.12988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 KÖŞger F, YİĞİtaslan S, EŞsİzoĞlu A, GÜleÇ G, KarataŞ RD, DeĞİrmencİ SS. Inflammation and Oxidative Stress in Deficit Schizophrenia. Noro Psikiyatr Ars 2020;57:303-7. [PMID: 33354123 DOI: 10.29399/npa.24966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Kogan S, Ospina LH, Kimhy D. Inflammation in individuals with schizophrenia - Implications for neurocognition and daily function. Brain Behav Immun 2018;74:296-9. [PMID: 30218782 DOI: 10.1016/j.bbi.2018.09.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
48 Werner MCF, Wirgenes KV, Shadrin AA, Lunding SH, Rødevand L, Hjell G, Ormerod MB, Haram M, Agartz I, Djurovic S, Melle I, Aukrust P, Ueland T, Andreassen OA, Steen NE. Limited association between infections, autoimmune disease and genetic risk and immune activation in severe mental disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2022. [DOI: 10.1016/j.pnpbp.2022.110511] [Reference Citation Analysis]
49 Kroken RA, Sommer IE, Steen VM, Dieset I, Johnsen E. Constructing the Immune Signature of Schizophrenia for Clinical Use and Research; An Integrative Review Translating Descriptives Into Diagnostics. Front Psychiatry. 2018;9:753. [PMID: 30766494 DOI: 10.3389/fpsyt.2018.00753] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
50 Wang Y, Zhan G, Cai Z, Jiao B, Zhao Y, Li S, Luo A. Vagus nerve stimulation in brain diseases: Therapeutic applications and biological mechanisms. Neurosci Biobehav Rev 2021;127:37-53. [PMID: 33894241 DOI: 10.1016/j.neubiorev.2021.04.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Essali N, Goldsmith DR, Carbone L, Miller BJ. Psychosis as an adverse effect of monoclonal antibody immunotherapy. Brain Behav Immun 2019;81:646-9. [PMID: 31170448 DOI: 10.1016/j.bbi.2019.06.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
52 Crockett AM, Ryan SK, Vásquez AH, Canning C, Kanyuch N, Kebir H, Ceja G, Gesualdi J, Zackai E, McDonald-McGinn D, Viaene A, Kapoor R, Benallegue N, Gur R, Anderson SA, Alvarez JI. Disruption of the blood-brain barrier in 22q11.2 deletion syndrome. Brain 2021;144:1351-60. [PMID: 33876226 DOI: 10.1093/brain/awab055] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
53 Wang Y, Wei Y, Edmiston EK, Womer FY, Zhang X, Duan J, Zhu Y, Zhang R, Yin Z, Zhang Y, Jiang X, Wei S, Liu Z, Zhang Y, Tang Y, Wang F. Altered structural connectivity and cytokine levels in Schizophrenia and Genetic high-risk individuals: Associations with disease states and vulnerability. Schizophr Res 2020;223:158-65. [PMID: 32684357 DOI: 10.1016/j.schres.2020.05.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Goldsmith DR, Rapaport MH. Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. Front Psychiatry 2020;11:46. [PMID: 32153436 DOI: 10.3389/fpsyt.2020.00046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]